IVI Submits Comments on ICER Draft Evidence Report on JAK Inhibitors for RA
IVI offered comments on ICER’s recently released Draft Evidence Report examining the cost-effectiveness of Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis. In addition to commenting on the needs for transparency and the impacts of modeling assumptions on results, IVI’s comments raise a broader question about the relevance of the analysis to decision making. IVI writes […]
Jennifer Bright Explains How IVI Economic Models Improve Process of Value Assessment
At the National Health Council’s event, Back to School: Patient Community Training on Value Assessment, IVI executive director Jennifer Bright explains the non-profit organization’s mission to make value assessment more relevant to real decision making, how and why patient perspectives must be built into the front end of economic modeling, and how patients and patient […]
Top Three Questions Employers Need to Ask Benefits Consultants
Jennifer Bright writes in Benefits Pro that employers who rely on health plans and vendors to advise them on coverage for drugs or other treatments need to ask several key questions to ensure they are getting the most value out of their consultants’ recommendations. Read the full article here.
IVI Comment Letter on ICER’s Proposed Methods for Curative Therapies
IVI submitted comments to ICER regarding proposed methodological changes for assessments of the value of single or short-term transformative (SST) therapies. IVI emphasized the need for ICER to address the potential use of its findings by decision makers, specifically when short-term budget estimates may discourage investment in therapies with high long-term value, including careful consideration […]
Watch Devin Incerti Discuss the Need for Adaptable Value Assessment Approaches
Devin Incerti sat down with the AJMC media team at the 2019 ISPOR conference to discuss how value is context-specific and therefore value assessment should be too. Watch the interview here.
2-Minute Drill: Jeroen Jansen on How to Improve Value Assessment
At the 2019 ISPOR conference, Jeroen Jansen sat down with AJMC to explain the current state of value assessment and how by putting patients at the frontend of analysis, we can better quantify the value of a treatment. Watch the brief interview here.
How IVI is Bringing Value to Cancer Care
After the release of the public comments for IVI-NSCLC, Managed Healthcare Executive took a look at IVI’s open-source model focusing on non-small lung cancer and how it will bring healthcare executives insight into value that otherwise wouldn’t exist with traditional models. Read the full article here.
IVI Announces a Request for Proposal (RFP)
IVI is committed to exploring scientifically rigorous methods that improve the practice of value assessment in a collaborative, iterative environment. To that end, we are pleased to announce the call for research proposals that help us advance our mission and demonstrate the applicability of patient-defined factors of value. IVI welcomes proposals from individual researchers as […]
5 Steps to Build an Active Learning System for Value Assessment
In the wake of this year’s ISPOR conference, IVI’s Executive Director, Jennifer Bright, reflects on how to move value assessment from a static snapshot in time to an active learning approach. She discusses the following five steps to improving value assessment: Take the transparency challenge. Embrace flexibility. Allow for iteration. Improve incorporation of non-clinical data. […]
Heard at ISPOR: Wide Ranging Podcast with IVI on Advanced Value Assessment Methods and the QALY Controversy
The IVI team sat down with the Journal of Clinical Pathways while at ISPOR for an in-depth discussion about why advanced value assessment is needed and how it’s progressing. The team also discussed the QALY – what it is and whether it can be improved. To listen to the podcast or read the transcript, click […]